Banque Cantonale Vaudoise Takes $1.76 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• Banque Cantonale Vaudoise acquired 9,987 shares of IQVIA Holdings Inc. in the first quarter, valued at approximately $1.76 million.
• Recent insider selling included Eric Sherbet, who sold 5,800 shares, decreasing his ownership by 17.59%.
• IQVIA's stock has a market cap of $32.55 billion and reported a 5.3% increase in quarterly revenue compared to the previous year.

Banque Cantonale Vaudoise acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 9,987 shares of the medical research company's stock, valued at approximately $1,760,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. American National Bank & Trust acquired a new stake in shares of IQVIA in the first quarter valued at approximately $26,000. Golden State Wealth Management LLC increased its stake in shares of IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares during the period. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA in the first quarter valued at approximately $33,000. ST Germain D J Co. Inc. increased its stake in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares during the period. Finally, GKV Capital Management Co. Inc. acquired a new position in shares of IQVIA during the fourth quarter valued at approximately $39,000. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Down 1.8%

Shares of IQVIA stock traded down $3.42 during midday trading on Friday, reaching $182.44. 1,644,130 shares of the company's stock traded hands, compared to its average volume of 2,321,248. The company has a market cap of $31.01 billion, a price-to-earnings ratio of 26.40, a price-to-earnings-growth ratio of 2.00 and a beta of 1.30. The company's 50 day simple moving average is $162.11 and its 200 day simple moving average is $169.89. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. IQVIA's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.64 EPS. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on IQV. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and lowered their price objective for the company from $260.00 to $160.00 in a research note on Friday, April 25th. Cowen reiterated a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Citigroup reiterated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Robert W. Baird raised their price objective on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Finally, Mizuho raised their target price on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Seven analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $228.62.

Insider Buying and Selling at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.